PLK1 blockade enhances the anti-tumor effect of MAPK inhibition in pancreatic ductal adenocarcinoma
Authors:
- Ben ZhaoBZBen Zhao
Open Access
- 7 April 2025
- journal article
- Published by Elsevier in Cell Reports
- Vol. 44 (4) , 115541
Abstract
No abstract availableKeywords
Funding Information
- Deutschen Konsortium für Translationale Krebsforschung
- Deutsche Krebshilfe (70115201/TACTIC)
- Deutsche Krebshilfe (70112505/PIPAC)
- Bundesministerium für Forschung, Technologie und Raumfahrt (01KD2206A/SATURN3)
- Deutsche Forschungsgemeinschaft (450917483/GRK2762/1)
- Deutsche Forschungsgemeinschaft (421166016/SI1549/4\u20131)
- Deutsche Forschungsgemeinschaft (405344257/SI1549/3-2)
- Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie
- Natural Science Foundation of Hubei Province (2024AFB034)
This publication has 46 references indexed in Scilit:
- Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasisCell Reports, 2021
- Clinical Development of BRAF plus MEK Inhibitor CombinationsTrends in Cancer, 2020
- Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic CancerCell, 2019
- Many ways to resistance: How melanoma cells evade targeted therapiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- NF-κB in pancreatic cancer: Its key role in chemoresistanceCancer Letters, 2018
- Employing Metabolism to Improve the Diagnosis and Treatment of Pancreatic CancerCancer Cell, 2017
- Organoid Models of Human and Mouse Ductal Pancreatic CancerCell, 2015
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasEuropean Journal of Cancer, 2014
- p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agentsCancer Letters, 2014
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapyInvestigational New Drugs, 2011